Latest News

Innova Biosciences Introduces InnovaGOLD Nanoparticles

August 28th, 2014

New ultra-high quality gold nanoparticles simplify assay development and improve the sensitivity of immunoassays Cambridge, UK, 28th August 2014: Innova Biosciences (Innova), a specialist provider of bioconjugation products and services, announced today the commercial launch of InnovaGOLD, a new range of ultra-high quality gold nanoparticles that have demonstrated improved sensitivity, stability and reproducibility in immunoassays…

View

Innova Biosciences and TGR BioSciences Announce Co-Marketing Agreement for Core Technologies

January 16th, 2014

Combining Innova’s Lightning-Link® conjugation kits with TGR’s CaptSure™ ELISA technology simplifies ELISA development and improves sensitivity Cambridge, UK and Adelaide, Australia, 16 January 2014: TGR BioSciences Pty Ltd (TGR), a life sciences company focused on the development of rapid, high sensitivity ELISA systems using their CaptSure technology, and Innova Biosciences (Innova), a specialist provider of…

View

Innova Biosciences Ltd achieves InnovaCoat® key scale-up target

November 12th, 2013

Innova Biosciences, the inventor of high quality, easy to use bioconjugation kits, is pleased to announce it has reached yet another significant milestone of its programme funded by the UK’s innovation agency, the Technology Strategy Board, by meeting a key scale-up target for the production of its unique InnovaCoat® gold nanoparticle conjugation reagents. Traditional passive…

View

Innova Biosciences Develops Site-Specific Bioconjugation Technology

August 27th, 2013

Innova Biosciences, the inventor of the world’s easiest to use antibody labeling kits, is pleased to announce the launch of a site-specific bioconjugation technology for attaching antibodies to gold nanoparticles. Innova’s core business is ‘bioconjugation’ – the joining of two molecules to form a hybrid ‘conjugate’. Conjugates are used in diagnostic tests in hospitals and…

View

VolitionRx to use Innova Biosciences’ Biotin Technology in its Epigenetic Research Kits

July 21st, 2013

In-licensing deal between VolitionRx and UK-based Innova Biosciences helps drive development of novel cancer diagnostics VolitionRx Limited (OTC: VNRX), a life sciences company focused on the development of blood-based diagnostic tests, has signed a non-exclusive in-licensing agreement with Innova Biosciences, a specialist provider of bioconjugation systems, based in Cambridge, UK. Under the agreement, Innova Biosciences…

View

Lightning-Link® In-licensing Deal Enhances ImmunoReagents’ Product Offering to the Diagnostic Industry

April 29th, 2013

ImmunoReagents, the global manufacturer of high quality antibody products to the diagnostic and research industry, has entered into a non-exclusive in-licensing deal to use Innova Biosciences (Cambridge, UK) Lightning-Link® technology for commercial purposes. Through the commercialisation deal, ImmunoReagents will utilise Innova’s technology for the manufacture of antibody conjugates, taking advantage of the very rapid Lightning…

View

Innova Biosciences Develops Technology to Increase Sensitivity of Diagnostic Tests

February 19th, 2013

World healthcare models are continuously facing financial challenges when it comes to providing for an ageing population. The current models for provision are increasingly questioned with the upward trend in healthcare spending becoming a significant portion of the GDP. One solution to alleviate the ever increasing burden is earlier detection of disease using more accurate…

View

Innova Biosciences is Proud to Announce Award of ISO 9001:2008 Certification

January 14th, 2013

Innova Biosciences (Cambridge, UK) the original manufacturer and provider of high quality bioconjugation services, used primarily in research, diagnostics and the biotech industry, announced today that it has recently achieved ISO 9001:2008 certification. Innova Biosciences has had its work processes accredited to internationally recognised quality management system (QMS) standards. In working towards this, every operational…

View